Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

This publication has 11 references indexed in Scilit:

• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
  The Lancet, 2007
• Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
  The Lancet, 2007
• Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis
  AIDS, 2007
• British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2006)
  HIV Medicine, 2006
• Treatment for Adult HIV Infection
  JAMA, 2006
• TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments
  Journal of Virology, 2005
• TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1
  Antimicrobial Agents and Chemotherapy, 2004
• Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals
  The Lancet, 2004
• Resistance profile and cross‐resistance of HIV‐1 among patients failing a non‐nucleoside reverse transcriptase inhibitor‐containing regimen*
  Journal of Medical Virology, 2001
• Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy
  Journal of Virology, 2001